Bright Minds Biosciences' BMB-101 shows promise in treating drug-resistant epilepsy. Read why DRUG stock is a strong ...

Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

Enrollment has finished for the Phase 3 RISE UP study, which is testing the oral therapy mitapivat in people with sickle cell ...

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptanceCompany also announces FDA End-of-Phase 2 in-person meeting ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

Dr. Thomas Wagner, founder of the biotech company Orbis Health Solutions and cancer researcher, has made it his life's mission to find a way to treat cancer without the dreaded side effects that ...

The initial trio of patients with glioblastoma have begun treatment with ropidoxuridine in a phase 2 clinical trial, ...

after its ORMD-0801 candidate missed the mark in a phase 3 trial. The announcement marks the disappointing end of a marathon effort by Oramed to develop an oral insulin formulation for type 2 ...

Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a ...

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt ... rezatapopt 500 mg once-daily in combination with pembrolizumab 200 mg every three weeks ...

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the ...

Both trials met their primary endpoints, indicating a significant improvement in patients treated with the drug.